Sushil Patel Adds to Holdings in Revolution Medicines, Inc.
Insider Sushil Patel purchased 3,127 shares of Revolution Medicines on June 18, 2026.
Key Points
- Sushil Patel bought 3,127 shares of Revolution Medicines, Inc. on June 18, 2026.
- Revolution Medicines, Inc. traded near $169.51 on Wednesday with a market cap of $35.3 billion.
- Analysts maintain a strong buy consensus with a mean price target of $187.29.
Important disclosure: Podchat is not a registered investment adviser, broker-dealer, or financial planner. This article is for informational and educational purposes only and is not a recommendation to buy, sell, or hold any security. Content may be generated by automated systems using public filings, market data, and third-party sources, and may contain errors or omissions. Investing involves risk, including possible loss of principal. Past performance, insider activity, analyst ratings, price targets, sentiment scores, and hypothetical or backtested results are not guarantees of future performance. Please do your own research and consult a qualified professional before making investment decisions.
Sushil Patel, an insider at Revolution Medicines, Inc. (NasdaqGS: RVMD), purchased 3,127 shares of the company on June 18, 2026. The stock was trading around $169.51 on Wednesday, reflecting the company's substantial market presence with a market cap of $35.3 billion.
Insider Buying and Selling at Revolution Medicines, Inc.
On June 18, 2026, several insiders at Revolution Medicines, including Sushil Patel, bought shares. Patel acquired 3,127 shares, while other insiders like Kim Lorence, Flavia Borellini, and Elizabeth Anderson also made similar purchases. These transactions were not part of any pre-planned 10b5-1 trading plans.
Revolution Medicines, Inc. Stock Down 18.5%
Shares of Revolution Medicines, Inc. traded near $169.51 on Wednesday. The company, with a market cap of $35.3 billion, is involved in the biotechnology sector, focusing on precision oncology. It has a forward P/E of -29.1 and a beta of 1.407. The stock's 52-week range is between $34.00 and $166.84, with a 50-day moving average of $146.50 and a 200-day moving average of $95.18. The company maintains a strong liquidity position with a current ratio of 6.80 and a quick ratio of 6.59.
$RVMD stock price
Daily closing prices, year to date. Not investment advice.
Analysts Set New Price Targets
Analysts continue to show confidence in Revolution Medicines, with Evercore ISI Group maintaining a 'buy' rating and setting a price target of $220 on June 10. RBC Capital also maintained a 'buy' rating with a target of $182 on June 2. Overall, the analyst consensus remains strong buy with an average price target of $187.29 from 21 analysts.
About Revolution Medicines
Revolution Medicines, Inc. is a biotechnology company based in Redwood City, California. It focuses on developing targeted therapies for RAS-addicted cancers. The company is led by CEO Dr. Mark A. Goldsmith and employs 883 people. Revolution Medicines works on RAS(ON) inhibitors, which are in various stages of clinical development, aimed at treating solid tumors and other cancer types.
Bottom Line
Insider activity at Revolution Medicines, including the recent purchase by Sushil Patel, reflects ongoing interest in the company's growth potential. The stock's trading price and market cap indicate strong market confidence. Analysts' ratings and price targets suggest continued optimism about the company's future prospects. As always, note that insider and analyst actions are based on past data and should be considered as part of broader investment research.
Get Revolution Medicines, Inc. alerts
New 13F filings, insider trades, and analyst moves on $RVMD, sent to your inbox. Free, and you can unsubscribe anytime.
This instant news alert was generated by automated narrative technology and financial data from Podchat and public regulatory filings. It is for informational purposes only and is not financial advice.